S1PR1 and myeloid sarcoma: This list encompassesvarious drug families, including kinase inhibitors like cabozantinib,alpha-1 adrenergic antagonists such as terazosin and dixazosin, andanti-inflammatory medications such as nabumetone and phenylbutazone.Notably, fingolimod, a chemically diverse compound with an inhibitoryeffect against sphingosine-1-phosphate receptor (S1P), which has beenapproved for the treatment of MS, is also present among these drugs. Its similarity index and chemical structureare reported in Table .